Eli Lilly, Chi-Med Team Up on Cancer Drugs
Eli Lilly & Co. announced it will work with a unit of Hutchison China MediTech Ltd., known as Chi-Med, to develop drugs to treat cancer and inflammatory diseases. Lilly will hand over preclinical research and development on several compounds to the pharmaceuticals company. Chi-Med, which is listed on London’s Alternative Investment Market, is a subsidiary of Hutchison Whampoa Ltd.
Read Original Post Here
Leave a Comment